ADAM17 and cardiomyopathy: To investigate the role of ADAM17 in doxorubicin-induced cardiac injury, a mouse model of doxorubicin-induced cardiomyopathy was established in the first proportion of the in vivo experiments (Fig. 1a), where doxorubicin was continuously administered to C57BL/6J male mice, once a week for 4 weeks, to achieve chronic cardiotoxicity.